CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech

• CureVac N.V. (NASDAQ: CVAC) has moved to assert its intellectual property rights, accumulated over two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development.

• CureVac has filed a lawsuit in the German Regional Court in Düsseldorf against BioNTech SE (NASDAQ: BNTX) and two of its subsidiaries, seeking fair compensation for infringement of a portfolio of CureVac’s intellectual property rights utilized in Comirnaty, BioNTech and Pfizer Inc’s (NYSE: PFE) mRNA COVID-19 vaccine.

• Related: CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial.

• CureVac does not seek an injunction nor intend to take legal action that impedes the production, sale, or distribution of Comirnaty by BioNTech and its partner Pfizer.

• The CureVac intellectual property portfolio protects multiple inventions considered essential to the design and development of BioNTech’s SARS CoV-2 mRNA vaccine, among others.

• These relate to the engineering of mRNA molecules, including sequence modifications to increase stability and enhance protein expression and mRNA vaccine formulations specific to SARS CoV-2 vaccines.

• Price Action: BNTX shares are down 5.17% at $149.35 during the premarket session on the last check Tuesday.

See more from Benzinga

• FDA Expert Panel Favors COVID-19 Boosters Targeting Omicron BA.4, BA.5 Subvariants

• This Analyst Says US Government Buying More COVID-19 Vaccines At Higher Prices

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.